Piper Sandler Upgrades Biogen to Overweight, Raises Price Target to $214

Benzinga Newsdesk www.benzinga.com Positive 86.5%

Neg 0% Neu 0% Pos 86.5%

Piper Sandler analyst David Amsellem upgrades Biogen (NASDAQ:BIIB) from Neutral to Overweight and raises the price target from $177 to $214.